CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 100 enrolled
Drug / intervention
Exparel +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04910165
NCT04910165Phase 3Completed
CompareCT.gov

Adductor Canal Blocks Using Exparel for Pain Control After Total Knee Arthroplasty

St. Luke's Hospital, Pennsylvania·interventional·Posted Jun 2, 2021·Updated May 20, 2022

In Brief

A Phase 3 clinical trial evaluating Exparel and Ropivacaine for Arthritis Knee and 2 related conditions. Completed, enrolled 100 participants across 1 site.

Detailed Summary

Exparel has been shown to have better pain control compared to previously used infiltration agents, including bupivacaine, while having a minor side effect profile. The purpose of this study is to explore the effectiveness of Exparel (liposomal bupivacaine) in Adductor Canal Blocks for peri-operative pain control following a total knee arthroplasty (TKA) procedure.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsArthritis Knee, Pain, Postoperative, Opioid Use
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
202120222023202420252026
First PostedJun 2, 2021
Enrollment StartJun 1, 2020
Primary CompletionSep 15, 2021
Study CompletionOct 15, 2021
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 5.1 years ago

Interventions

Expareldrug

Exparel used in Adductor Canal Block plus Infiltration Between Popliteal Artery and Capsule of Knee using Ropivacaine

Ropivacainedrug

Ropivacaine used in Adductor Canal Block plus Infiltration Between Popliteal Artery and Capsule of Knee using Ropivacaine